[go: up one dir, main page]

DK0600866T3 - Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler - Google Patents

Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler

Info

Publication number
DK0600866T3
DK0600866T3 DK91910915.7T DK91910915T DK0600866T3 DK 0600866 T3 DK0600866 T3 DK 0600866T3 DK 91910915 T DK91910915 T DK 91910915T DK 0600866 T3 DK0600866 T3 DK 0600866T3
Authority
DK
Denmark
Prior art keywords
methods
preparations
biologically active
active molecules
identifying biologically
Prior art date
Application number
DK91910915.7T
Other languages
English (en)
Inventor
James J Devlin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0600866T3 publication Critical patent/DK0600866T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91910915.7T 1990-06-01 1991-05-13 Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler DK0600866T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53318090A 1990-06-01 1990-06-01

Publications (1)

Publication Number Publication Date
DK0600866T3 true DK0600866T3 (da) 1998-03-09

Family

ID=24124831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910915.7T DK0600866T3 (da) 1990-06-01 1991-05-13 Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler

Country Status (10)

Country Link
EP (1) EP0600866B1 (da)
JP (1) JPH05507700A (da)
AT (1) ATE160818T1 (da)
AU (2) AU8081491A (da)
CA (1) CA2084307A1 (da)
DE (1) DE69128362T2 (da)
DK (1) DK0600866T3 (da)
ES (1) ES2109945T3 (da)
GR (1) GR3025596T3 (da)
WO (1) WO1991018980A1 (da)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
DE69229222D1 (de) * 1991-03-07 1999-06-24 Bradbury Auswahl spezifischer proteine durch ein biologisches verfahren
ATE414768T1 (de) * 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993007169A1 (en) * 1991-10-04 1993-04-15 Chiron Corporation Peptide inhibitors of platelet adhesion
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0663953B1 (en) * 1992-09-04 2001-12-05 The Scripps Research Institute Phagemids coexpressing a surface receptor and a surface heterologous protein
US6955900B1 (en) 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
AU684510B2 (en) * 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
IT1261693B (it) * 1993-06-01 1996-05-29 Angeletti P Ist Richerche Bio Metodologia per la produzione di fagi filamentosi che espongono sulla superficie del capside peptidi capaci di legare la biotina, e fagi filamentosi e peptidi cosi' ottenibili.
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
ATE217344T1 (de) * 1994-09-21 2002-05-15 Cytogen Corp Antigen bindende peptide (abtides) aus peptidbibliotheken
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
KR20020086508A (ko) 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
US7129326B2 (en) 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
DK1360500T3 (da) 2000-04-14 2010-05-25 Genencor Int Fremgangsmåde til selektiv målretning
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
MXPA04009778A (es) 2002-04-08 2004-12-13 Pionner Hi Bred International Exsercion de fibra sedosa mejorada bajo estres.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP1590453B1 (en) 2003-01-28 2013-11-27 Cellectis Custom-made meganuclease and use thereof
JP2006516639A (ja) 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005013889A2 (en) 2003-05-19 2005-02-17 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
BRPI0417689A8 (pt) 2003-12-17 2017-04-25 Elan Pharm Inc Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
DK1701968T3 (da) 2003-12-17 2015-06-22 Wyeth Llc Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006135382A2 (en) 2004-08-04 2006-12-21 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
ATE549624T1 (de) 2005-07-01 2012-03-15 Arbor Vita Corp Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
WO2007030560A2 (en) 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CA2626325A1 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals Incorporated Methods for identifying compounds of interest using encoded libraries
US7935344B2 (en) 2005-12-29 2011-05-03 Centocor Ortho Biotech Inc. Human anti-IL-23 antibodies, compositions, methods and uses
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
ES2546863T3 (es) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
BRPI0819743A2 (pt) 2007-11-20 2014-10-07 Pioneer Hi Bred Int Ácido nucléico isolado, cassete de expressão, célula hospedeira, planta transgênica, semente transgênica, método para modular a resposta de etileno em uma planta, proteína isolada
EP2231181B1 (en) 2007-12-17 2016-02-17 Marfl AB New vaccine for the treatment of mycobacterium related disorders
EA028356B1 (ru) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
WO2010021415A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
SI2356269T1 (sl) 2008-10-31 2016-10-28 Janssen Biotech, Inc. Ogrodni sestavki, postopki in uporabe na osnovi domene fibronektina tipa III
CA2752211C (en) 2009-02-12 2020-03-24 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
WO2011017492A2 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
US11225655B2 (en) 2010-04-16 2022-01-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2012162514A2 (en) 2011-05-26 2012-11-29 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
EP2758775B1 (en) 2011-09-22 2017-08-16 Medicinal Bioconvergence Research Center Novel use of leucyl trna synthetase
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
WO2013044029A1 (en) 2011-09-23 2013-03-28 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN103906835A (zh) 2011-10-25 2014-07-02 先锋国际良种公司 改变植物细胞壁组成以改善生物燃料生产和青贮饲料可消化性的方法
CN105247056A (zh) 2013-03-15 2016-01-13 先锋国际良种公司 Acc脱氨酶表达的调节
CN105308073B (zh) 2013-06-14 2019-08-13 加利福尼亚太平洋生物科学股份有限公司 双生物素化标签
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
JP2018513166A (ja) 2015-04-20 2018-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 系統的な探索、成熟化および伸長プロセスにより同定した、タンパク質に対する特異的ペプチドバインダー
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US10852309B2 (en) 2015-08-25 2020-12-01 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP2019528428A (ja) 2016-06-20 2019-10-10 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 自己免疫疾患の鑑別診断方法
JP2019526786A (ja) 2016-06-20 2019-09-19 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 自己免疫疾患の診断および処置のための方法
AU2017292172A1 (en) 2016-07-06 2019-01-03 Prothena Biosciences Limited Assay for detecting total and S129 phosphorylated alpha-synuclein
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
AU2017296237A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
WO2018064436A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CA3043264A1 (en) 2016-11-11 2018-05-17 Healthtell Inc. Methods for identifying candidate biomarkers
IL323048A (en) 2016-11-16 2025-10-01 Janssen Biotech Inc Method for treating psoriasis with a specific anti-IL-23 antibody
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
EP3579871A4 (en) 2017-02-07 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS
JP7206227B2 (ja) 2017-03-13 2023-01-17 ポセイダ セラピューティクス，インコーポレイティド 造血幹細胞の選択的除去と置換のための組成物と方法
WO2018202850A1 (en) 2017-05-05 2018-11-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
CA3072777A1 (en) 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP3790587A4 (en) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
CA3120237A1 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES
AU2019401282A1 (en) 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
KR20210141998A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
CN113825769A (zh) 2019-03-14 2021-12-21 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
CN113840838A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的制造方法
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
CA3136119A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
CA3142665A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2020245766A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2020342544A1 (en) 2019-09-05 2022-03-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US20230079955A1 (en) 2019-12-20 2023-03-16 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CA3174777A1 (en) 2020-04-14 2021-10-21 Eric M. Ostertag Compositions and methods for use in the treatment of cancer
BR112022022378A2 (pt) 2020-05-05 2022-12-13 Janssen Biotech Inc Métodos para tratamento da doença de crohn com anticorpo específico anti-il23
WO2021234634A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4231999B1 (en) 2020-10-21 2025-03-05 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
JP2024536310A (ja) 2021-10-04 2024-10-04 ポセイダ セラピューティクス，インコーポレイティド トランスポゾン組成物及びその使用方法
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP4465962A1 (en) 2022-01-21 2024-11-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2026003761A1 (en) 2024-06-27 2026-01-02 Janssen Biotech, Inc. Methods of treating ulcerative colits with anti-il23 specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
AU4308689A (en) * 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods

Also Published As

Publication number Publication date
WO1991018980A1 (en) 1991-12-12
DE69128362T2 (de) 1998-05-20
JPH05507700A (ja) 1993-11-04
AU3310595A (en) 1996-02-22
EP0600866A1 (en) 1994-06-15
AU699732B2 (en) 1998-12-10
CA2084307A1 (en) 1991-12-02
ATE160818T1 (de) 1997-12-15
EP0600866B1 (en) 1997-12-03
DE69128362D1 (de) 1998-01-15
GR3025596T3 (en) 1998-03-31
AU8081491A (en) 1991-12-31
ES2109945T3 (es) 1998-02-01

Similar Documents

Publication Publication Date Title
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
NO911694D0 (no) Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav.
DE68924026D1 (de) Biosensor und dessen herstellung.
ATE112963T1 (de) Gewebeentzusammensetzung und verfahren.
FI920664A7 (fi) Menetelmä hammas- ja sairaanhoidon alalla käytettävien restauraatioide n, proteesien tai vastaavien valmistamiseksi
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DE59008160D1 (de) Feste pharmazeutische Präparate und Verfahren zu ihrer Herstellung.
DE122011100046I1 (de) In vitro kulturprozess fur verschiedene stadien von gewebeparasiten.
DE59008901D1 (de) Vorrichtung zur Erstellung von medizinischen, insbesondere zahnmedizinischen, Prothetik- Passkörpern.
DE69016245D1 (de) Artikel zur Gewebekonditionierung.
DK109590A (da) Biologisk aktivt protein
NO903801D0 (no) Alkalipullunase, mikroorganisme og fremgangsmaate ved fremstilling derav.
IT1226386B (it) Procedimento di preparazione di morniflumato e analoghi.
NO902248D0 (no) Renininhiberende peptider, deres fremstilling og anvendelse i legemidler.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
ATE137487T1 (de) Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren
IT1261386B (it) Peptidi modificati con gruppo fosfinico per la marcatura con 99m-tc e 186-188-re o agenti paramagnetici.
DE59003312D1 (de) Verwendung von Diphenyletherderivaten zur Desikkation und Abszission von Pflanzenorganen.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
FI910933A7 (fi) Kiinteät silikonikoostumukset, joilla on maanviljelyksessä aktiivinen biologinen vaikutus
DE69103388D1 (de) Thexyl-(C1-C4)alkyl-dialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
NO905221D0 (no) Steriliseringsblandinger og anvendelse derav.